Roche sues Biocon over proposed breast-cancer drug copy
Reuters2026/07/30 15:34Adds response from Genentech spokesperson in bullet 3
By Blake Brittain
July 30 (Reuters) - Roche's ROPC.S Genentech has sued Indian biopharmaceutical company Biocon BION.NS in New Jersey federal court, alleging its proposed biosimilar of Genentech's blockbuster breast-cancer drug Perjeta would infringe Genentech's patents.
Genentech asked the court in a lawsuit filed on Wednesday to block Biocon from making or selling its biosimilar.
A Biocon spokesperson declined to comment on the lawsuit on Thursday, citing pending litigation.
"We respect the legal process and will defend our patents," a Genentech spokesperson said.
Biosimilars are versions of biologic drugs that are comparable to generics of traditional pharmaceuticals. Unlike traditional drugs, complex biologic drugs are made from living cells and cannot be copied exactly.
Genentech's biologic Perjeta was Switzerland-based Roche's sixth-best-selling drug last year, earning the company nearly CHF 2.97 billion ($3.67 billion) worldwide, according to a company report.
Genentech separately filed a complaint at the U.S. International Trade Commission in February seeking to block Biocon from importing its biosimilar, but withdrew the complaint in June after Biocon said the imports were not for commercial distribution.
(Reporting by Blake Brittain in Washington)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Nvidia quietly reduces OpenAI data center guarantee from 250 billions to below 120 billions
Nvidia and OpenAI are close to signing a data center financing agreement in Ohio. However, Nvidia's financial guarantee has been reduced from $250 billion to less than $120 billion, covering only about 5 GW of computing power for the project's first phase. This adjustment is a direct response to investor concerns about Nvidia's risk exposure—after the previous $250 billion guarantee plan was revealed, Nvidia's stock price fell 5% in a single day. The agreement could be signed as early as this weekend.
Ivy League’s space gamble: Harvard reveals $2.2 billions SpaceX position, its largest single stock holding
Harvard University Investment Management Company disclosed that it holds $2.2 billion worth of SpaceX shares, making it the largest single stock position in its $4.3 billion US equity portfolio. This holding originated from Harvard’s early investment in SpaceX through venture capital funds, and the position has significantly appreciated after SpaceX’s public listing in June this year. The University of California also disclosed a roughly $1 billion position in SpaceX during the same period. Over the past decade, endowment funds from several universities have made substantial bets on private tech assets.
Crypto prices
More
